Gisslen M - Search Results

1

Biotypes of Central Nervous System Complications in People With Human Immunodeficiency Virus: Virology, Immunology, and Neuropathology.

Joseph SB, Gianella S, Burdo TH, Cinque P, Gisslen M, Letendre S, Nath A, Morgello S, Ndhlovu LC, Spudich S. Joseph SB, et al. Among authors: gisslen m. J Infect Dis. 2023 Mar 17;227(Suppl 1):S3-S15. doi: 10.1093/infdis/jiac370. J Infect Dis. 2023. PMID: 36930640 Free PMC article.

2

Intrathecal immunoactivation in patients with HIV-1 infection is reduced by zidovudine but not by didanosine.

Hagberg L, Norkrans G, Gisslen M, Wachter H, Fuchs D, Svennerholm B. Hagberg L, et al. Among authors: gisslen m. Scand J Infect Dis. 1996;28(4):329-33. doi: 10.3109/00365549609037914. Scand J Infect Dis. 1996. PMID: 8893393 Clinical Trial.

3

The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine.

Gisslén M, Norkrans G, Svennerholm B, Hagberg L. Gisslén M, et al. J Infect Dis. 1997 Feb;175(2):434-7. doi: 10.1093/infdis/175.2.434. J Infect Dis. 1997. PMID: 9203666

4

Biomarkers of HIV-1 CNS infection and injury.

Price RW, Epstein LG, Becker JT, Cinque P, Gisslen M, Pulliam L, McArthur JC. Price RW, et al. Among authors: gisslen m. Neurology. 2007 Oct 30;69(18):1781-8. doi: 10.1212/01.wnl.0000278457.55877.eb. Neurology. 2007. PMID: 17967994 Review.

5

Response to: 'How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?'.

Winston A, Cotter A, Gisslen M, Mallon P, Cinque P. Winston A, et al. Among authors: gisslen m. HIV Med. 2020 Aug;21(7):e17-e18. doi: 10.1111/hiv.12874. Epub 2020 May 22. HIV Med. 2020. PMID: 32441846 Free article. No abstract available.

6

Rebound HIV-1 in cerebrospinal fluid after antiviral therapy interruption is mainly clonally amplified R5 T cell-tropic virus.

Kincer LP, Joseph SB, Gilleece MM, Hauser BM, Sizemore S, Zhou S, Di Germanio C, Zetterberg H, Fuchs D, Deeks SG, Spudich S, Gisslen M, Price RW, Swanstrom R. Kincer LP, et al. Among authors: gisslen m. Nat Microbiol. 2023 Feb;8(2):260-271. doi: 10.1038/s41564-022-01306-6. Epub 2023 Jan 30. Nat Microbiol. 2023. PMID: 36717718 Free PMC article.

7

Changes in Cerebrospinal Fluid Proteins across the Spectrum of Untreated and Treated Chronic HIV-1 Infection.

Hu Z, Cinque P, Dravid A, Hagberg L, Yilmaz A, Zetterberg H, Fuchs D, Gostner J, Blennow K, Spudich SS, Kincer L, Zhou S, Joseph S, Swanstrom R, Price RW, Gisslén M. Hu Z, et al. Among authors: gisslen m. bioRxiv [Preprint]. 2024 May 5:2024.05.03.592451. doi: 10.1101/2024.05.03.592451. bioRxiv. 2024. PMID: 38746436 Free PMC article. Preprint.

8

Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study.

Gisslén M, Chiodi F, Fuchs D, Norkrans G, Svennerholm B, Wachter H, Hagberg L. Gisslén M, et al. Scand J Infect Dis. 1994;26(5):523-33. doi: 10.3109/00365549409011810. Scand J Infect Dis. 1994. PMID: 7855550

9

Cerebrospinal fluid and plasma viral load in HIV-1-infected patients with various anti-retroviral treatment regimens.

Gisslén M, Svennerholm B, Norkrans G, Franzén C, Säll C, Svensson R, Oberg S, Hagberg L. Gisslén M, et al. Scand J Infect Dis. 2000;32(4):365-9. doi: 10.1080/003655400750044926. Scand J Infect Dis. 2000. PMID: 10959643

10

Antiretroviral treatment of central nervous system HIV-1 infection: a review.

Gisslén M, Hagberg L. Gisslén M, et al. HIV Med. 2001 Apr;2(2):97-104. doi: 10.1046/j.1468-1293.2001.00056.x. HIV Med. 2001. PMID: 11737386 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

295 results

Search Page